平衡期对比增强多排CT测定的细胞外容积分数作为不可切除胰腺腺癌化疗预后的预后因素
研究纳入67例组织学确诊的不可切除胰腺腺癌患者,化疗前行对比增强多排CT,计算肿瘤对比增强和细胞外容积分数。中位总生存期10.5个月,多因素分析显示仅肿瘤细胞外容积分数是总生存期的独立预测因素(HR 0.97,p=0.012)。
要点
- 化疗前平衡期增强CT可定量肿瘤细胞外容积分数。
- 肿瘤细胞外容积分数较高者化疗后预后较好。
- 多因素分析中细胞外容积分数为独立预后因素。
核心结论
- 平衡期对比增强多排CT测定的细胞外容积分数可能是有用的影像生物标志物,用于预测不可切除胰腺腺癌患者化疗后的生存。
研究设计与样本
- 研究纳入67例(男42例,女25例;平均年龄67.5岁,范围45-83岁)组织学确诊的手术不可切除胰腺腺癌患者,在全身化疗前接受对比增强多排CT检查。
关键影像表现/征象
- 在胰腺腺癌和主动脉区域兴趣区测量平扫与平衡期增强CT,计算肿瘤对比增强和细胞外容积分数。
- 单因素分析显示血清CA19-9升高(HR 1.00;p=0.006)和CEA升高(HR 1.02;p=0.011)与总生存期不良相关。
诊断标准与关键数值
- 单因素分析显示肿瘤对比增强增加(HR 0.98;p<0.001)和细胞外容积分数增加(HR 0.97;p=0.001)与总生存期良好相关。
- 多因素分析显示仅肿瘤细胞外容积分数是总生存期的独立预测因素(HR 0.97;p=0.012)。
- 中位总生存期为10.5个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess whether extracellular volume (ECV) fraction with equilibrium contrast-enhanced multidetector computed tomography (MDCT) predicts outcomes for unresectable pancreatic adenocarcinoma patients treated with chemotherapy METHODS: Sixty-seven patients (42 men, 25 women; mean age, 67.5 years; range, 45-83 years) with histologically confirmed surgically unresectable pancreatic adenocarcinoma underwent contrast-enhanced MDCT before systemic chemotherapy. Tumour contrast enhancement (CE) and ECV fraction were calculated using region-of-interest measurement within the pancreatic adenocarcinoma and aorta on unenhanced and equilibrium phase-enhanced CT. The effect on survival variables including age, sex, tumour location, tumour size, TNM stage, carbohydrate antigen (CA) 19-9, carcinoembryonic antigen (CEA), tumour CE and tumour ECV fraction was determined on univariate and multivariate analyses using Cox proportional hazards regression model.
RESULTS: Median overall survival was 10.5 months. On univariate analysis, elevated serum CA19-9 (hazard ratio (HR), 1.00; p = 0.006) and CEA (HR, 1.02; p = 0.011) levels were found to be associated with a negative effect on overall survival. Increasing tumour CE (HR, 0.98; p < 0.001) and ECV fraction (HR, 0.97; p = 0.001) were associated with a positive effect. Multivariate analysis revealed that only tumour ECV fraction was an independent predictor of overall survival (HR, 0.97; p = 0.012).
CONCLUSIONS: ECV fraction with equilibrium contrast-enhanced MDCT could be a useful imaging biomarker for predicting patient survival after chemotherapy for unresectable pancreatic adenocarcinoma.
KEY POINTS: • Tumour aggressiveness and response to therapy are influenced by the extravascular extracellular space. • Extracellular volume (ECV) fraction can be quantified with equilibrium contrast-enhanced CT. • Patients with higher tumour ECV fraction had better prognosis after chemotherapy.
引用
- Fukukura Y, Kumagae Y, Higashi R, et al. Extracellular volume fraction determined by equilibrium contrast-enhanced multidetector computed tomography as a prognostic factor in unresectable pancreatic adenocarcinoma treated with chemotherapy. Eur Radiol. 2018. PMID: 29922930. doi:10.1007/s00330-018-5570-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。